TrialInternational journal of rheumatic diseases2020

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.

Rieke Alten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.